Arbutus Biopharma Corp (ABUS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.05 (-0.39%), Market cap $0.84B, P/E ratio 5.10, 52-week low–high $3.09 ~ $4.95.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technolo
Financial statements, price targets, institutional (13F) holdings and related news for Arbutus Biopharma Corp are updated in real time on BlackAll Trade.
Arbutus Biopharma Corp trades at $5.05 (-0.39%). Real-time quotes and charts are available on BlackAll Trade.
Arbutus Biopharma Corp has a market cap of about $0.84B. Its P/E ratio is 5.10.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline compr